Breakthrough Device Designation for miR Sentinel™ urine test

According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …

miR Sentinel tests 90+ percent accurate in diagnosis of prostate cancer

Earlier this year, at the annual Genitourinary Cancer symposium in San Francisco, we were first given information about the potential of three new tests for the diagnosis of prostate cancer: the so-called miR Sentinel tests from miR Scientific. … READ MORE …

The pros and cons of “screening” for prostate cancer

A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …

New urine test shows promising results in detecting, classifying risk for prostate cancer

A newly published article in BJU International has described a way to test post-DRE urine samples for the presence of specific types of ribonucleic acid (RNA) and use these data to detect and classify risk levels for more and less aggressive forms of prostate cancer. … READ MORE …

Genomic data and prostate cancer risk classification: an update

Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …

Conflicts of interest always present problems (to some degree)

As our friend Howard Wolinsky continues his journalistic exploits into the world of prostate cancer, he has (almost inevitably) come across an issue of “conflicts of interest”, … READ MORE …

What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

Germline genetic testing for men with prostate cancer

In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …

Good news and less good news for OPKO Diagnostics

So first the “less good” news … READ MORE …

Back to basics: two useful articles to pass along

The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …

The development of a “10-minute cancer test”: the Methylscape

By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …

Medicare to cover costs of new test for AR-V7

We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …

Germline mutations and risk for advanced prostate cancer

Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …

Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

Prostate cancer and its management: where we are at now

A relatively long article in the June 21 issue of US News & World Report discusses a series of topical issues related to the diagnosis and management of prostate cancer, including: … READ MORE …